Could a common diabetes drug help fight a deadly lung disease?
NCT ID NCT07520110
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether metformin, a standard diabetes medicine, can slow the worsening of idiopathic pulmonary fibrosis (IPF), a serious lung disease. About 400 high-risk patients will receive either metformin or a placebo. The goal is to see if metformin can delay death, hospital stays, or the need for a lung transplant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Massachusetts Chan Medical School
Worcester, Massachusetts, 01655, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill slow lung scarring in IPF?
- Beyond the lungs: the hidden emotional toll of IPF medications
- Can umbilical cord stem cells ease a scarring lung disease?
- Spotting hidden blood clots in scarred lungs: a study hunts for clues
- What makes someone stop a lung fibrosis drug? a study asks patients directly
- A smarter way to track lung disease? new platform aims to personalize COPD and IPF care